Results 151 to 160 of about 16,492 (195)

Differential expression of POMC-processing genes in corticotroph tumors. [PDF]

Endocr Oncol
Lamback E, Miranda RL, Mendonça L, de Figueiredo CS, Salum KCR, Dezonne RS, Wildemberg LE, Gadelha MR.   +7 more
europepmc   +1 more source

High levels of serum cholesterol increase the risk of developing vessel co-opting tumors in colorectal cancer liver metastases. [PDF]

FEBS J
Gantz A, Kapelanski-Lamoureux A, Rada M, Krzywon L, Tsamchoe M, Tsatoumas A, Petrillo SK, Seidah NG, Lazaris A, Metrakos P.   +9 more
europepmc   +1 more source

Ezetimibe vs Inclisiran in Coronary Artery Disease and Hyperlipidemia: A Propensity-Matched Analysis. [PDF]

JACC Adv
Akbar UA, Ijaz H, Banga A, Cheshire M, Shakeel S, Jena N, Alexander T, Dani SS.   +7 more
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis

openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Natural Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Review

Combinatorial Chemistry and High Throughput Screening, 2023
Abstract: PCSK9 (proprotein convertase subtilisin/kexin type 9) is an enzyme that helps to reduce cardiovascular events. This clinical result is attributable primarily to the crucial involvement of PCSK9 in regulating the low-density lipoprotein cholesterol level.

exaly   +3 more sources

Proprotein convertase subtilisin/kexin type 9 inhibition

Current Opinion in Lipidology, 2012
There are now ample data that demonstrate that inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) can safely lower LDL cholesterol synergistically with statins. Considering that PCSK9 was first identified less than a decade ago, the last few years have shown rapid and remarkable advancements in our understanding and knowledge of the ...
David A, Marais, Dirk J, Blom, Francine, Petrides, Yann, Gouëffic, Gilles, Lambert   +4 more
openaire   +2 more sources

Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism

2020
Plasma levels of cholesterol, especially low-density lipoprotein cholesterol (LDL-C), are positively correlated with the risk of cardiovascular disease. Buildup of LDL in the intima promotes the formation of foam cells and consequently initiates atherosclerosis, one of the main underlying causes of cardiovascular disease. Hepatic LDL receptor (LDLR) is
Shoudong, Guo, Xiao-Dan, Xia, Hong-Mei, Gu, Da-Wei, Zhang   +3 more
openaire   +2 more sources

Proprotein convertase subtilisin/kexin type 9

Current Opinion in Cardiology, 2018
This review describes the pivotal role of genetic insights and technologies in the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the rapid development of PCSK9 inhibitors - a revolutionary new class of lipid-lowering agents.PCSK9 was discovered as a the third gene implicated in familial hypercholesterolemia. Population genetics
Robert M, Stoekenbroek, John J P, Kastelein   +1 more
openaire   +2 more sources

Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors

Current Opinion in Cardiology, 2016
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors are promising therapies that inhibit the degradation of low-density lipoprotein (LDL) receptors in the hepatocyte and thus increase LDL cholesterol (LDL-C) uptake from the blood. This review summarizes main findings in the field of PCSK9 inhibitors, from basic mechanism to clinical ...
Alon, Eisen, Robert P, Giugliano
openaire   +2 more sources